{
    "nctId": "NCT00121134",
    "briefTitle": "Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer",
    "officialTitle": "Anti-Angiogenesis Treatment After Preoperative Chemotherapy: A Pilot Study in Women With Operable Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 164,
    "primaryOutcomeMeasure": "The Completion Rate of 1 Year of Bevacizumab Therapy for All Four Cohorts",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging\n* Patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. No more chemotherapy should be planned.\n* Patients must have completed definitive resection of primary tumor with adequate excision of gross disease.\n* For patients receiving adjuvant radiation therapy, treatment must be completed prior to initiation of protocol therapy.\n* Patients must have the presence of significant residual invasive disease on pathologic review following their preoperative chemotherapy.\n* LVEF \\> institutional limits of normal after preoperative chemotherapy, as assessed by ECHO or nuclear medicine gated study, within 30 days prior to initiating protocol-based treatment.\n* ECOG performance status 0-1\n\nExclusion Criteria:\n\n* Inadequate organ function, as measured by laboratory assessment after preoperative chemotherapy and within 14 days of beginning protocol-based treatment\n* Patients with metastatic disease are ineligible.\n* Known HIV infection\n* Patients may not be pregnant, expect to become pregnant, plan to conceive a child while on study, or breastfeeding\n* Uncontrolled intercurrent illness\n* Non-healing wounds or major surgical procedures (such as breast surgery) other than that for venous access device or diagnostic study are not permitted within 28 day prior to enrollment\n* History of abdominal fistula, GI perforation, intra-abdominal abscess, or serious, non-healing wound, ulcer, or bone fracture within 6 months prior to initiating bevacizumab\n* Patients with any history of arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular event (CVA), unstable angina, or myocardial infarction (MI) within the past 6 months. Patients with clinically significant peripheral arterial disease should also be excluded\n* History of bleeding diathesis or coagulopathy\n* History of grade 3 or 4 allergic reactions to compounds of similar chemical or biologic composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites)\n* Prior history of malignancy treated without curative intent, excluding nonmelanomatous skin cancer\n* Patients with large or rapidly accumulating pleural or abdominal effusions\n* Current use of anticoagulants is allowed as long as patients have been on a stable dose for more than two weeks with stable INR\n* Chronic therapy with full dose aspirin (\\< 325 mg/day) or standard non-steroidal anti-inflammatory agents is allowed\n* Patients may not receive other investigational agents while on study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}